The Medicines Evaluation Board (MEB) assesses and guards the efficacy, safety and quality of both human and veterinary medicinal products. In the case of novel foods submitted for authorisation, the MEB assesses their safety.

The MEB

• occupies a prominent position in the European authorisation agency market.
• considers the protection of public health the main focus of its assessment and monitoring activities.
• is the primary source of information on new medicinal products, new applications and current risk information and works actively to communicate this information.
• aims to achieve maximum transparency in its processes.
• offers added value, derived from its work in assessing and monitoring the efficacy, safety and risks of medicinal products and from the scientific advice it gives.